GRADE 3B FOLLICULAR LYMPHOMA
Clinical trials for GRADE 3B FOLLICULAR LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new GRADE 3B FOLLICULAR LYMPHOMA trials appear
Sign up with your email to follow new studies for GRADE 3B FOLLICULAR LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for lymphoma patients: drug cocktail aims to boost standard chemo
Disease control Recruiting nowThis study tests whether adding three targeted antibodies (tafasitamab, retifanlimab, and rituximab) to standard chemotherapy can safely and effectively treat adults with untreated diffuse large B-cell lymphoma. The goal is to improve cancer-killing power while managing side effe…
Matched conditions: GRADE 3B FOLLICULAR LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated May 26, 2026 07:00 UTC
-
Double-Barreled CAR t cells take on tough lymphomas
Disease control Recruiting nowThis early-phase study tests a new type of CAR T cell therapy that targets two proteins (CD79b and CD19) on lymphoma cells. It is for people with non-Hodgkin lymphoma that has come back or not responded to standard treatments. The main goals are to check safety and find the right…
Matched conditions: GRADE 3B FOLLICULAR LYMPHOMA
Phase: PHASE1 • Sponsor: Marcela V. Maus, M.D.,Ph.D. • Aim: Disease control
Last updated May 26, 2026 06:49 UTC
-
New hope for lymphoma patients: drug cocktail aims to control cancer without transplant
Disease control Recruiting nowThis study tests whether adding either tazemetostat or zanubrutinib to a standard two-drug therapy (tafasitamab and lenalidomide) can better control relapsed or refractory large B-cell lymphoma in people who are not eligible for a stem cell transplant. About 227 participants will…
Matched conditions: GRADE 3B FOLLICULAR LYMPHOMA
Phase: PHASE2 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated May 26, 2026 06:47 UTC
-
Can a one-two punch after CAR t keep lymphoma away?
Disease control Recruiting nowThis study is for people with certain types of lymphoma that came back or didn't respond to treatment. After receiving CAR T-cell therapy, participants will get one or two additional drugs (mosunetuzumab and/or polatuzumab vedotin) to see if they help keep the cancer from returni…
Matched conditions: GRADE 3B FOLLICULAR LYMPHOMA
Phase: PHASE2 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated May 22, 2026 14:03 UTC